- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07223125
Eine Studie zu JNJ-89862175 zur Behandlung von fortgeschrittenen soliden Tumoren
Eine Phase-1-Studie von JNJ-89862175, einem Ektonukleotid-Pyrophosphatase/Phosphodiesterase-Familienmitglied-3-Antikörper-Wirkstoff-Konjugat, für fortgeschrittene solide Tumore
The purpose of this study is to determine safe and effective dose (recommended phase 2 doses [RP2Ds]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Study Contact
- Telefonnummer: 844-434-4210
- E-Mail: Participate-In-This-Study1@its.jnj.com
Studienorte
-
-
-
Lyon, Frankreich, 69373
- Rekrutierung
- Centre Leon Berard
-
Villejuif, Frankreich, 94805
- Rekrutierung
- Gustave Roussy
-
-
-
-
-
Seoul, Südkorea, 06351
- Rekrutierung
- Samsung Medical Center
-
Seoul, Südkorea, 03722
- Rekrutierung
- Severance Hospital Yonsei University Health System
-
-
-
-
Florida
-
Orlando, Florida, Vereinigte Staaten, 32803
- Rekrutierung
- AdventHealth Orlando
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Rekrutierung
- Massachusetts General Hospital Cancer Center
-
-
Texas
-
Irving, Texas, Vereinigte Staaten, 75039
- Rekrutierung
- NEXT Oncology
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participants must have histologically or cytologically confirmed, metastatic or unresectable solid tumor of lung adenocarcinoma, renal cell carcinoma (RCC): clear cell or papillary carcinoma, endometrioid ovarian cancer and endometrioid uterine carcinoma
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 at screening
- Participants on study drug and for 4 months after the last dose of study drug must not breastfeed or be pregnant, not donate gametes (that is, eggs or sperms) or freeze for future use for the purposes of assisted reproduction and wear an external condom
Exclusion Criteria:
- Active central nervous system (CNS) involvement unless clinically stable
- History of clinically significant cardiovascular disease within 6 months prior to signing informed consent
- History of solid organ or hematologic stem cell transplantation
- Known allergies, hypersensitivity, or intolerance to excipients of JNJ-89862175
- Has prior or concurrent second malignancy (other than the disease under study) in which the natural history or treatment is likely to interfere with safety endpoints or efficacy of the study drug
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: JNJ-89862175
Participants will receive JNJ-89862175 in Part 1 to determine the recommended phase 2 doses (RP2Ds). Dose-escalation and de-escalation will be based on study evaluation team (SET) decision. In Part 2, participants will receive JNJ-89862175 at the RP2Ds determined in Part 1. |
JNJ-89862175 will be administered. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs)
Zeitfenster: Up to 21 days
|
The DLTs are specific adverse events that includes high grade hematologic or non-hematologic toxicities with exceptions and/or toxicities leading to treatment discontinuation. |
Up to 21 days
|
|
Part 1: Number of Participants with Adverse Events (AEs) by Severity
Zeitfenster: Up to 2 years and 10 months
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product and does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to 2 years and 10 months
|
|
Part 2: Number of Participants with Adverse Events (AEs) by Severity at RP2D
Zeitfenster: Up to 2 years and 10 months
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product and does not necessarily have a causal relationship with the intervention. Severity will be graded according to the NCI-CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to 2 years and 10 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective Response Rate (ORR)
Zeitfenster: Up to 2 years and 10 months
|
ORR is defined as the percentage of participants who have best overall response of complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version (v.) 1.1. |
Up to 2 years and 10 months
|
|
Progression Free Survival (PFS)
Zeitfenster: Up to 2 years and 10 months
|
PFS is defined as the time from the first dose of JNJ-89862175 to either disease progression according to RECIST v. 1.1, or death due to any cause, whichever comes first. |
Up to 2 years and 10 months
|
|
Duration of Response (DOR)
Zeitfenster: Up to 2 years and 10 months
|
DOR is defined as the time from the date of initial documentation of a response to the date of first documented evidence of disease progression according to RECIST v. 1.1, or death due to any cause, whichever occurs first. |
Up to 2 years and 10 months
|
|
Maximum Plasma Concentration (Cmax) for JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Zeitfenster: Up to 2 years and 10 months
|
Serum samples will be analyzed to determine Cmax of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite. |
Up to 2 years and 10 months
|
|
Observed Plasma Concentration Immediately Before Next Dose Administration (Ctrough) of JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Zeitfenster: Up to 2 years and 10 months
|
Ctrough of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite will be reported. |
Up to 2 years and 10 months
|
|
Time to Reach Cmax (Tmax) for JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Zeitfenster: Up to 2 years and 10 months
|
Tmax defined as the the time to reach maximum observed plasma concentration of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite will be reported. |
Up to 2 years and 10 months
|
|
Area Under the Plasma Concentration - Time (AUC [0-t]) Curve for JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Zeitfenster: Up to 2 years and 10 months
|
AUC (0-t) defined as area under the plasma concentration-time curve during a dosing interval of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite will be reported. |
Up to 2 years and 10 months
|
|
Accumulation Ratio of JNJ-89862175 (Total and Conjugated Antibody, Free Payload and Major Metabolite)
Zeitfenster: Up to 2 years and 10 months
|
Accumulation ratio of JNJ-89862175 with total and conjugated antibody, free payload and major metabolite will be reported. |
Up to 2 years and 10 months
|
|
Number of Participants With Anti JNJ-89862175 Antibodies
Zeitfenster: Up to 2 years and 10 months
|
Serum samples will be analyzed for the detection of anti-JNJ-89862175 antibodies using a validated assay method. |
Up to 2 years and 10 months
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- 89862175LUC1001
- 89862175LUC1001 (Andere Kennung: Janssen Research & Development, LLC)
- 2025-521407-52-00 (Registrierungskennung: EUCT number)
- 2025 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .